Cases
Derma Sciences, Inc. (NASDAQ: DSCI)
Merger
Overview
Overview
- Date:
- 2/2/2017
- Company Name:
- Derma Sciences, Inc.
- Stock Symbol:
- DSCI
- Company Name - Buyer:
- Integra Lifesciences Holdings Corporation
- Class Period:
- FROM 1/30/2017
- Status:
- Closed/Complete
- Merger Announcement Date:
- 1/10/2017
- Court:
- U.S. Bankruptcy Court: District of New Jersey
NEW YORK, February 2, 2017 – Bragar Eagel & Squire, P.C. announces that a class action lawsuit has been filed in the United States District Court for the District of New Jersey on behalf of all persons or entities who held Derma Sciences, Inc. (NASDAQ: DSCI) securities on January 30, 2017 (the “Class Period”).
On January 10, 2017, the two parties announced the signing of a definitive merger agreement pursuant to which Integra Lifesciences Holdings Corporation will acquire Derma Sciences, Inc. As a result of the merger, Derma Sciences shareholders are only anticipated to receive $7.00 per share in cash for common stock, $32.00 per share for Series A Convertible Preferred Stock, and $48.00 per share for Series B Preferred Stock.
The complaint alleges that the company failed to conduct a fair sales process and failed to disclose all material information regarding the sale of the company.
If you held Derma securities during the Class Period, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Melissa A. Fortunato, Esq. by email at investigations@bespc.com, or telephone at (212) 355-4648, or by filling out the contact form below. There is no cost or obligation to you.
On January 10, 2017, the two parties announced the signing of a definitive merger agreement pursuant to which Integra Lifesciences Holdings Corporation will acquire Derma Sciences, Inc. As a result of the merger, Derma Sciences shareholders are only anticipated to receive $7.00 per share in cash for common stock, $32.00 per share for Series A Convertible Preferred Stock, and $48.00 per share for Series B Preferred Stock.
The complaint alleges that the company failed to conduct a fair sales process and failed to disclose all material information regarding the sale of the company.
If you held Derma securities during the Class Period, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Melissa A. Fortunato, Esq. by email at investigations@bespc.com, or telephone at (212) 355-4648, or by filling out the contact form below. There is no cost or obligation to you.